Idarubicin  | | Systematic (IUPAC) name | | (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxo-α-L-lyxo-hexopyranoside | | Identifiers | | CAS number | 58957-92-9 | | ATC code | L01DB06 | | PubChem | 42890 | | DrugBank | APRD00126 | | Chemical data | | Formula | C26H27NO9 | | Mol. mass | 497.494 g/mol | | Synonyms | 9-acetyl-7-(4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl)oxy-6,9,11-trihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione | | Pharmacokinetic data | | Bioavailability | ? | | Protein binding | 97% | | Metabolism | ? | | Half life | 22 hours | | Excretion | ? | | Therapeutic considerations | | Pregnancy cat. | ? | | Legal status | | | Routes | ?
| Idarubicin (pronounced /ˌаɪdəˈruːbəsɪn/) or 4-demethoxydaunorubicin is an anthracycline antileukemic drug that is currently combined with cytosine arabinoside as a first line treatment of acute myeloid leukemia. It belongs to the family of drugs called antitumor antibiotics. FDA approved label can be found here. It is distributed under the trade names Zavedos (UK) and Idamycin (USA).
|
